The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.

Allogene Therapeutics, a US-based oncology treatment developer backed by pharmaceutical firm Pfizer, closed $120m in convertible note financing yesterday in an offering including the University of California (UC) office of the chief investment officer. Hedge fund sponsor Perceptive Advisors led the transaction, which also included Deerfield Management, Fidelity Management and Research, Franklin Templeton Investments, Jennison…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.